Pemirolast Potassium

About Haorui Products Technology Contact
 

 

 

Pemirolast Potassium API

 

Haorui supplies high quality Pemirolast Potassium API produced by our GMP facility that has been successfully inspected by the FDA. We offer competitive prices and support our products with reliable technical and regulatory services.  Pemirolast Potassium API is available from R&D to commercial quantities. Please contact us for more details.
 

  The following information is provided for general information purposes ONLY.
 
Pemirolast Potassium Description
ALAMAST® (pemirolast potassium ophthalmic solution) is a sterile, aqueous ophthalmic solution with a pH of approximately 8.0 containing 0.1% of the mast cell stabilizer, pemirolast potassium, for topical administration to the eyes.

Pemirolast potassium is a slightly yellow, water-soluble powder with a molecular weight of 266.3.

The chemical structure is presented below:

ALAMAST® (pemirolast potassium) Structural Formula Illustration

C10H7KN6O

Chemical name

9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-α] pyrimidin-4-one potassium

Each mL contains: ACTIVE: pemirolast potassium 1 mg (0.1%); PRESERVATIVE: lauralkonium chloride 0.005%; INACTIVES: glycerin, dibasic sodium phosphate, monobasic sodium phosphate, phosphoric acid and/or sodium hydroxide to adjust pH, and purified water. The osmolality of ALAMAST® oph-thalmic solution is approximately 240 mOsmol/kg.

 

Pemirolast Potassium Indications

ALAMAST® ophthalmic solution is indicated for the prevention of itching of the eye due to allergic conjunctivitis. Symptomatic response to therapy (decreased itching) may be evident within a few days, but frequently requires longer treatment (up to four weeks).

 

Pemirolast Potassium Dosage and Administration

The recommended dose is one to two drops in each affected eye four times daily.

Symptomatic response to therapy (decreased itching) may be evident within a few days, but frequently requires longer treatment (up to four weeks).

 

Pemirolast Potassium Side Effects

In clinical studies lasting up to 17 weeks with ALAMAST® ophthalmic solution, headache, rhinitis, and cold/flu symptoms were reported at an incidence of 10–25%. The occurrence of these side effects was generally mild. Some of these events were similar to the underlying ocular disease being studied.

The following ocular and non-ocular adverse reactions were reported at an incidence of less than 5%:

Ocular: burning, dry eye, foreign body sensation, and ocular discomfort.

Non-Ocular: allergy, back pain, bronchitis, cough, dysmenorrhea, fever, sinusitis, and sneezing/nasal congestion.

 

Pemirolast Potassium Patents 1

Pemirolast Potassium Patents 2

Pemirolast Potassium Patents 3

  
  Haorui - Your Partner to Pharmaceutical Success - Copy Right Reserved